FCF Fox Corporate Finance GmbH freut sich den neuen “FCF Healthcare & Life Sciences Venture Capital Monitor – USA 05/2025” zu veröffentlichen.
Der FCF Healthcare & Life Sciences Venture Capital Monitor – USA ist eine monatlich erscheinende Übersicht von Finanzierungstrends im Venture Capital Bereich mit Schwerpunkt auf US Healthcare & Life Sciences Unternehmen.
As of the end of May 2025 we identified the following current VC trends in the United States:
- Total Healthcare & Life Sciences funding reached EUR 15,796m (-9% vs. 2024)
- Biotech/Pharma received 40% of the total investment volume (EUR 6,357m) with oncology being the leading indication (27%)
- In May Neuralink secured the highest transaction volume with EUR 576m, followed by Pathos with EUR 327m and Lumicell with EUR 176m
- Illumina (United States) is the most active investor (by deal volume in 2025), followed by Regeneron Pharmaceuticals (United States) and Bain Capital Life Sciences (United States)
Um den gesamten Report zu lesen, klicken Sie hier.
Von Mathias Klozenbücher und Johannes Link